

References

I-9173

1. Radicava prescribing information. Mitsubishi Tanabe Pharma Corporation. May 2022.
2. Kiernan M. C., Vucic S., Cheah B. C., Turner M. R., Eisen A., Hardiman O., et al. (2011). Amyotrophic lateral sclerosis. *Lancet* 377 942–955. 10.1016/S0140-6736(10)61156-7.
3. Miller R.G., Jackson C.E., Kasarskis E.J., England J.D., ForsheW D., Johnston W., Kalra S., Katz J.S., Mitsumoto H., Rosenfeld J., et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American of Neurology. 2009;73:1227–1233.
4. Koji Abe, Mashashi Aoki, Shoji Tsuji, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomized double-blind, placebo-controlled trial. *Lancet Neurology*. 2017 May 15, S1474-4422(17)30115-1.
5. Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Apr. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK542359/>.
6. Oskarsson B., Gendron T., Staff N. Amyotrophic Lateral Sclerosis: An Update for 2018. *Mayo Clin Proc*. 2018;93(11):1617-1628.